At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HDV iShares Core High Dividend ETF
Post-Market Trading 04-02 18:38:55 EDT
120.16
-0.35
-0.29%
盘后118.88
-1.28-1.07%
18:00 EDT
| High120.39 | Low119.34 | Vol425.54K |
| Open120.19 | D1 Closing120.51 | Amplitude0.88% |
| Mkt Cap11.38B | Tradable Cap11.38B | Total Shares94.70M |
| T/O51.04M | T/O Rate0.45% | Tradable Shares94.70M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Press Release: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
Dow Jones · 03-20
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
Business Wire · 03-13
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
GlobeNewswire · 02-26
HEXAOM Strengthens Market Position with HDV Group Acquisition
TIPRANKS · 01-29
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
GlobeNewswire · 2024-12-26
Hexaom SA Expands with HDV Group Acquisition
TIPRANKS · 2024-12-24
Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
Dow Jones · 2024-12-19
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Business Wire · 2024-12-12
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Business Wire · 2024-11-19
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Business Wire · 2024-11-18
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
GlobeNewswire · 2024-11-07
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Business Wire · 2024-10-15
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
GlobeNewswire · 2024-09-23
Introduction
Company Name.
iShares Core High Dividend ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App